MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41392-026-02655-y

Медицинская библиотека · Signal transduction and targeted therapy · 2026

Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes.

Aboelella Nada S, Park Ryan, Tang Erting, Asby Nicholas, Ho Joshua D, Pan Tony, Wang Sidney, Xie Lishi, Kline Justin P, Riedell Peter A, Huang Jun, LaBelle James L

СтатьяПеревод в очереди

Аннотация

Targeting the BCL-2 family of proteins, key regulators of cellular apoptosis, with BH3-mimetics has been a major therapeutic goal to overcome cancer cell death resistance. However, beyond their canonical roles in apoptosis, BCL-2 proteins also play vital roles in cellular metabolism, signaling, and, increasingly, immune cell regulation. T cells in particular depend heavily on BCL-2 family proteins during ontogeny and maintenance, yet the broader consequences of pharmacologically inhibiting anti-apoptotic BCL-2 proteins in T cells remain underexplored. Our group has previously demonstrated that BCL-2 inhibition with the BH3-mimetic venetoclax induces gene expression and plasticity changes in murine T cells. Building upon this, we here investigate whether venetoclax-driven T cell reprogramming can be leveraged to enhance adoptive cell therapies, specifically using chimeric antigen receptor (CAR) T cells targeting CD19 as a model system. Our findings reveal that venetoclax treatment during ex vivo expansion of CART cells, prepared from T cells from healthy donors or chemotherapeutically pretreated patients, potently augments antitumor efficacy in a BCL-2-dependent manner. Transcriptomic and functional analyses demonstrate that venetoclax reprograms CART cells by regulating signaling pathways (e.g., IL-2/STAT5 and PI3K/AKT) and metabolic programs (e.g., OXPHOS and glycolysis), yielding CART cells with superior fitness and effector functionalities. These results highlight a novel therapeutic approach using anti-apoptotic drugging to enhance the performance of adoptive T cell therapies and support further examination of venetoclax and other BH3-mimetics as immune modulators.

Для цитирования: Aboelella Nada S, Park Ryan, Tang Erting, Asby Nicholas, Ho Joshua D, Pan Tony, Wang Sidney, Xie Lishi, Kline Justin P, Riedell Peter A, Huang Jun, LaBelle James L. Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes.. Signal transduction and targeted therapy. 2026. DOI: 10.1038/s41392-026-02655-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.